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Introduction
been previously recognized to have prognostic value in the management and treatment of breast 48 cancer patients [1] . During the last decade, there have been several commercially accepted multi-49 gene prognostic tests. Genomic prognostic tests have been associated with decreased adjuvant 50 chemotherapy use among patients, and better outcomes with cost-effective treatments [2] . 51
However, the availability and expense of these genomic tests remain largely prohibitive for 52 constrain-resourced hospital settings, regardless of country income. For example, in the United 53
States, the use of the 21-gene recurrence score Oncotype DX has increased significantly over the 54 last decade due to insurance coverage, but it is estimated that only a quarter of eligible patients 55 have been tested [3] . 56
In resource-constrained settings, the use of surrogate immunohistochemistry (IHC)-based 57 breast cancer subtypes presents as an alternative to molecular subtyping when there is no access 58 to gene expression data or high-throughput sequencing data. Despite the lowering costs of 59 genomic tests, these technologies are only available to researchers in select locations in the 60 world, and they are inaccessible to most patients worldwide. Alternatively, a panel of three IHC 61 markers-estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth 62 factor receptor 2 (HER2)-demonstrated its predictive value for chemotherapy response in 63 breast cancer [4] . There are other IHC markers that could be included for the prediction of 64 treatment response and prognosis; however, further studies are needed to select an optimized 65 surrogate panel [5] . 66
The 2015 Mexican Consensus on diagnosis and treatment of breast cancer [6] is the main 67 working document for oncologists in the country. It recommends routine use of a 3-marker panel 68 (ER, PR, HER2) IHC approximation to identify four intrinsic breast cancer phenotypes (luminal 69 A, luminal B, HER-2, and triple negative). In the Mexican population, the estimated frequency 70 of ER/PR positive is 60%, HER2 positive 20.4%, and triple negative is 23.1% [7, 8] . There is a 71 troubling onset of disease among younger breast cancer patients in Mexico (aged <40), with a 72 high prevalence of triple-negative breast cancers [9] . Furthermore, there is an increased mortality 73 trend associated with breast cancer in the country [10] . 74
The Mexican clinical practice guidelines for screening, management, and treatment of 75 breast cancer [11] [12] [13] also recommends the use of IHC testing as part of the histopathology 76 studies. Despite these recommendations, the widespread use of genetic testing in Mexico remains 77 elusive due to constrained resources. However, IHC testing is widely available through hospital-78 owned pathology laboratories, as well as through outsourced commercial laboratories across the 79
country. 80
In this study, we aimed to assess the timeliness of surrogate IHC biomarker testing in the 81 context of a resource-constrained hospital setting. Evaluating the therapeutic value for patients is 82 of critical importance, since the demand for more IHC testing will create new logistical 83 challenges in the healthcare system. The impact of acceptable or critical time delays is ultimately 84 not well defined, and it would be of great importance for hospital administrators to have a 85 reference of the value of timely IHC testing. As precision medicine continues to provide better 86 prognostic biomarkers, translating these benefits into clinical practice increasingly requires a 87 time-efficient approach from the entire healthcare system. 88 
Methods

90
Ethical approval 91
Hospital setting 101
The Mexican Institute of Social Security is a hybrid single-payer system with an 102 integrated network of hospitals nationwide. In Michoacan (a state located in western Mexico), 103 the General Regional Hospital No. 1 (HGR1) is the designated secondary-care facility for the 104 IMSS-insured population, estimated at 1,288,695 people (28% of the state's population), out of 105 4,584,471 according to the 2015 census [14] . 106
This hospital is in Charo, a suburban community adjacent to the Michoacan capital 107 (Morelia), and it was built in 2012 to replace the old general hospital. HGR1 is the reference 108 secondary-care facility, which serves as reference for seven General Zone Hospitals and 45 109
Family Medicine Units within the state of Michoacan. HGR1 has an oncology unit with a full 110 complement of fixed staff and facilities available to all patients. It also offers pathology services, 111 diagnostic imaging, and therapeutic capabilities with access to all approved drugs. Patients with 112 breast cancer who require chemotherapy are sent to the outpatient medical unit, and patients with 113 breast cancer who require radiation therapy are provided the service through an outsourced 114 private service in the same city. The personnel include gynecologists, medical oncologist, 115 surgical oncologists with significant breast cancer training, adequate numbers of nursing and 116 pharmacy staff, surgeons with significant training, and cancer pathologists. A self-assessment of 117 the services and facilities provided by these hospitals is S1 Text, which is based upon a modified 118 version of the oncological service self-assessment levels for low-and middle-income countries 119 developed by The International Society of Pediatric Oncology (SIOP) committee on Pediatric 120
Oncology in Developing Countries (PODC) [15] . 121
Patients 123
The study population for this research was all cumulative breast cancer patients seen in 124 2014 by medical staff at the IMSS's General Regional Hospital No 1 in Charo, Michoacan. The 125 institution's breast cancer census was used to select patients that were seen in 2014 at HGR1. To 126 avoid selection bias in our study, we did not restrict the selection of patients to members of the 127 female sex or any age group. The inclusion criteria can be seen in Figure 1 . We reviewed the medical records (both electronic and paper) of all breast cancer patients 142 at HGR1, and selected those whose biopsies had also been tested with IHC to detect ER, PR, 143 HER2 antibodies; then, we followed the medical histories of those patients, ending with March 144 2017, making note of multiple medical visits to the breast cancer clinic, medical oncology 145 service, and/or surgical oncology service. From their medical records, we extracted information 146 about IHC testing (antibody ordered, date of ordering, date of results being obtained), 147 chemotherapy and hormonal drugs administered, and radiation sessions and surgical procedures 148
Study design 151
This was a retrospective hospital-based cohort study, using medical records collected 152 routinely as part of clinical care. The objective was to understand the therapeutic impact on 153 breast cancer patients of the time taken to test surrogate immunohistochemistry biomarkers (ER, 154 PR, HER2) in a resource-constrained hospital in western Mexico. We were interested in 155 reporting the frequency of treatment selection or treatment adjustment frequencies depending on 156 breast cancer subtyping and the turnaround times for surrogate immunohistochemistry biomarker 157 testing. The analysis included timeline trajectories and association rules. The STROBE checklist 158 is provided in S2 Text. All analyses were performed in R version 3.3.2. 159 Timeline trajectories. We explored the paper-and electronic-based medical records for 160 all patients with IHC testing, from the patient's first day at the hospital to the last follow-up 161 pertaining to this study (occurring before March 2017). First, author MFRM manually reviewed 162 the patient's medical records and curated a set of possible events (transactions) that occurred to 163 the patients of this study, annotating the time points for each event for each patient. Then, author 164 ALP annotated those events with standardized coding from the Unified Medical Language 165 System (UMLS). When disagreement occurred, both authors discussed the translation to assign a 166 UMLS code to the medical records in Spanish. Finally, similar events were grouped together in 167 fewer categories. The UMLS codes, UMLS descriptions, Spanish description, and groupings can 168 be seen in Table 1 . 169  Table 1 . List of medical events with UMLS codes and descriptions in English and Spanish. 171
UMLS code UMLS description Description in Spanish
Visit C0008952 Clinic Visits Atención inicial en la unidad de medicina familiar (primer nivel de atención).
C2153644
Visit for: gynecological exam Atención inicial en la consulta de ginecología (segundo nivel de atención).
Oncology
C1620996
Oncology; primary focus of visit; workup, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)
Atención inicial en la consulta de oncología médica.
C1617848
Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancerdirected therapy is being administered or arranged at present; cancer-directed therapy might be considered in the future (for use in a medicare-approved demonstration project)
Atención subsecuente en la consulta de oncología médica. 
Request lab
172
Missing data. Missing data was assumed to be non-missing at random (NMAR), and the 173 events from Table 1 were considered missing for a specific reason. For example, if the code 174 C2186775 (request lab result from MRI) was missing from a patient's medical record, we left 175 that value unassigned, since it was assumed that an MRI was not requested for that patient. There 176 is a small chance that this assumption might be violated (and introduce some bias) if the 177 physician did request the exam/procedure but forgot to write it down in the medical record. 178
However, we did not impute any missing data, since that might be a larger source of bias for this 179 EHR-based data. 180
Outliers. We assessed the time-to-event distribution for each event in Table 1 , and 181 reported the mean time using boxplots with whiskers. The outliers were identified using the 1.5 182 interquartile rule, but were not removed from the downstream analysis since undefined time-to-183 event standards exist for these events. 184
Clustering. A heatmap with all the patients and events was generated. We used 185 hierarchical clustering to create dendograms. The distance matrix was generated with the time- 
Results
198
The epidemiological information obtained pertaining to this one IMSS hospital can be 199 seen in Consensus. Even in this small cohort, we can still see the same higher prevalence of triple 205 negative breast cancer cases that was previously reported [17] . It is troubling to see that there 206 were 18 (4% of) patients younger than 40 years old. 207
At IMSS, patients with Breast Imaging Reporting and Data System (BIRADS) reports 208 scoring 1 or 2 are usually deemed low-risk for breast cancer and they have regular annual 209 screenings at their Family Medicine Unit (UMF). Meanwhile, patients with BIRADS reports 0 210 and 3 are sent to IMSS's secondary care breast cancer clinic for a closer screening (usually fine-211 needle biopsy and 6-month screening); while patients with BIRADS reports 4, 5 or 6 are sent 212 directly to the secondary or tertiary care oncology services. At the IMSS-HGR1 hospital that we 213 investigated, 23 patients (6%) had a BIRADS score of 2 or lower, which were not supposed to be 214 sent to the secondary care facility. In these cases, patients had external biopsy investigations in 215 non-IMSS hospitals (usually private), and decided to continue their care for follow-up treatment 216 at the IMSS oncology services. 217 218 
220
Clustering analysis 221
A hierarchical clustering and heatmap of time-to-events is shown in Figure 2 . The time in 222 which each event occurred for each patient is measured using information found in their medical 223 record (in days, positive). To be able to create a dissimilarity matrix to calculate distance 224 between patients, all missing values were assigned a negative value of -1000. It is important to 225 note that this figure does not provide a context for the ordering in which events occurred, but it 226
can still help to provide information about patients with similar trajectories. Three main groups 227 of patients (or clusters) were identified in this graph. The time-to-event for all events is shown in Figure 4 . It is measured as the number of 252 days that it took for an event to occur, from the initial visit to the hospital stay (day 0). From this 253 Figure, it is easy to see that visiting the hospital or beginning treatment occurred relatively at the 254 beginning of the patients' trajectories, while events that typically take place later did in fact 255 occur at a posterior time, such as remission or metastasis. Also, one can see there is a wide 256 distribution of time, when requesting laboratory/imaging testing, which coincides with the 257 continuity of care. 258 which the data falls in the distribution. The diamond mark indicates that the treatment was 280 adjusted, according to protocols, after obtaining IHC results. The blue dashed line indicates the 281 1 st quartile for the time it took before an IHC request was submitted. Violin plots with whiskers 282 are correspondingly provided for the time to IHC request (from start to request), time to IHC 283 results (from start to the obtaining of results), and turnaround time of IHC testing (from request 284 to results). 285
Association rules 286
Association rules were mined from the events of this cohort using the Apriori algorithm. 287
The five top-ranking association rules are shown in Figure 6 . These rules have a support of 288 63.3% of cases, with a confidence of 90.5% and a rule performance (lift, or precision) of 1.3. For 289 rules with lift larger than 1, it can be assumed that the right-hand side of the rule is a 290 consequence of the left-hand side. In our mined rules, we can observe that, in general, IHC 291 testing, particularly ER/PR testing, results in adjusting treatment plans. 
Discussion
297
Key findings 298
Breast cancer in Mexico (and worldwide) continues to be a public health concern, and 299 increasing research is being done on the characterization of better genomic variants. Although 300 our study investigated a small number of patients, the prevalence and epidemiological 301 characteristics among our cohort are similar to what has previously been estimated for the 302 country (i.e. in regards to age group and staging) [10]. Our study further investigates the 303 timeliness of IHC testing, so our conclusions can then be used to inform hospital administrators 304 and public health officials around the world about the importance of timely IHC testing. 305
On the therapeutic value. The therapeutic importance of immunophenotyping (the use of 306 IHC testing for subtyping of cancer patients) needs to be carefully considered and addressed in 307 treatment plans by oncologists. IMSS protocol states that estrogen positive (ER+) and/or 308 progesterone positive (PR+) patients could benefit from hormone replacement therapy to prevent 309 recurrence. For the patient, that usually means that the traditional FEC chemotherapy regimen 310 composed by 5-fluorouracil, epirubicin, and cyclophosphamide, would be adjusted to include 311 some hormone replacement therapy, either aromatase inhibitors to block estrogen production 312 (e.g. anastrozole, letrozole, or exemestane), or some drug that could interfere with the ability of 313 estrogene to stimulate the growth of breast cells (e.g. tamoxifene or toremifene). 314
In contrast, patients with HER2 positive (HER2+), which tumors tend to grow and spread 315 more aggressively, could benefit from a targeted therapy that could prescribe drugs to block 316 HER2 (e.g. trastuzumab or pertuzumab). However, the use of these drugs can have different side 317 effects than traditional chemotherapy. The use of in situ hybridization (ISH), instead of IHC, can 318 be used to determine HER2 status with an overall concordance with IHC, and it may be more 319 beneficial to use both [18] . There is a need to balance sensitivity of the study with hospital 320 workload and expenses. Furthermore, HER2 status has been successfully incorporated into 321 medical practice to guide treatment decisions for breast cancer patients [19] . In fact, the 322 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated 323 their 2013 guidelines to designate more patients as eligible for trastuzumab therapy, in 324 accordance with ISH and IHC testing [20] . 325
On the timeliness of testing. Opportune IHC testing, understood as the availability of IHC 326 results before the beginning of any treatment, is of critical importance. For IMSS, the timeliness 327 of IHC results were typically not opportune, but whenever they were available, they triggered a 328 response from the clinical oncology team to adjust patient treatments. The widespread 329 distribution of time to request and turnaround time demonstrates the lack of standardization of 330 this process. Many factors could have contributed to the delay in IHC testing, including: patient 331 non-adherence to appointments; hospital overflow, resulting in longer appointments; logistical 332 problems relating to IHC testing's status an external service to the IMSS hospital of this study; 333 and administrative problems in the hospital resulting in inadequate tracking of tests and results. 334
On the need for improved clinical guidelines. It is important to establish an appropriate 335 timeline for opportune IHC testing. For example, In the United States, the College of American 336
Pathologists' (CAP) guideline on turnaround time for standard biopsies is around two days for 337 90% of cases [21] . In fact, the joint guideline on HER2 testing from the American Society of 338
Clinical Oncology (ASCO) and CAP recommends informing the patients about the expected 339 turnaround time [22] . In Australia, a study with more than 78,000 patients tested for HER2 340 status, with both ISH and IHC, revealed that the average turnaround time was between 4-5 days, 341 which decreased due to the increased volume of patients being tested [23] . In Saudi Arabia, a 342 study in 2015 showed that 24% of cases fall outside the recommended CAP turnaround time 343 On the need for accurate electronic health records (EHR). Missing information was 363 common across the paper and electronic records in our study. Clinicians and administrative staff 364 at the IMSS hospital are still getting used to the novel implementation of the EHR, which had an 365 impact on our ability to better characterize this cohort. In the absence of a cancer registry, our 366 best estimate of the disease is the institutional census. As the hospitals in Mexico, and elsewhere, 367 continue to become more and more electronic, there is a need to develop better software tools to 368 analyze the information obtained, including medical natural language processing and machine 369 learning applications. 370
On the visual representation. The medical trajectories shown in Figure 1 are useful in 371 quickly providing a patient history overview of hospital care. With more work on the user 372 interface, we envision this tool could eventually represent a valuable visual aid in which a patient 373 and their companions might be able to better communicate with their clinicians about the 374 management of their disease (it could probably also appear in a printed version). Currently, some 375 of the challenges of this tool include the missing identification of events that are overlapping, 376 and the impossibility of further elaborating on the details of each event. For a hospital 377 administrator, Figure 1 can provide a quick overview of the patients seen in their hospital, which 378 could be used as a decision-making tool, with the proper validation. This visual aid creation tool 379 can be obtained from the repository at https://github.com/arturolp/patientTrajectory.git 380 381
Healthcare system implications 382
Adverse events in the trajectory of an oncological patient, which might include 383 hospitalization related to cancer, recurrence of tumor, or metastasis, are extremely costly for the 384 healthcare system. The use of IHC testing was shown in our study to help with the selection of 385 precise treatment for patients (either by adjusting the treatment or confirming it). The association 386 rules found in our study confirm that ER and PR testing are associated with the adjustment of 387 treatment. However, the time in which IHC testing is performed is of critical importance if we 388 want to influence improved prognosis. 389 IHC testing is being carried out as an external service at the IMSS hospital in our study. 390
As the Mexican healthcare system continues to transition from reactive to preventative care, the 391 need for more IHC testing in breast cancer and other diseases will certainly allow for the further 392 development of its own testing facilities, therefore allowing for some economy of scale. 393
We have shown that the use of surrogate immunohistochemistry, as described by the 394 Mexican Consensus and previous literature worldwide, can have a beneficial therapeutic effect 395 on breast cancer patients. The aims of any healthcare system should be the identification of 396 earlier events that can have an impact on downstream events in the trajectory of an oncological 397 patient's treatment. In resource-constrained settings, it is important not only to consider surrogate 398 alternatives to more costly diagnostics (e.g. genomic testing), but also to incorporate the 399 regulatory and logistical aspects of implementing these surrogate IHC tests. IMSS must face the 400 important challenge of continuing to improve their turnaround times, which should have a 401 positive impact on the prognosis of their patients. Finally, other healthcare systems would also 402 benefit from determining the maximum turnaround time in which IHC testing can still be 403 opportune and have a therapeutic beneficial effect. 404
